Literature DB >> 32151314

Fatal amyloid formation in a patient's antibody light chain is caused by a single point mutation.

Pamina Kazman1, Marie-Theres Vielberg1, María Daniela Pulido Cendales2, Lioba Hunziger1, Benedikt Weber1, Ute Hegenbart3, Martin Zacharias2, Rolf Köhler4, Stefan Schönland3, Michael Groll1, Johannes Buchner1.   

Abstract

In systemic light chain amyloidosis, an overexpressed antibody light chain (LC) forms fibrils which deposit in organs and cause their failure. While it is well-established that mutations in the LC's VL domain are important prerequisites, the mechanisms which render a patient LC amyloidogenic are ill-defined. In this study, we performed an in-depth analysis of the factors and mutations responsible for the pathogenic transformation of a patient-derived λ LC, by recombinantly expressing variants in E. coli. We show that proteolytic cleavage of the patient LC resulting in an isolated VL domain is essential for fibril formation. Out of 11 mutations in the patient VL, only one, a leucine to valine mutation, is responsible for fibril formation. It disrupts a hydrophobic network rendering the C-terminal segment of VL more dynamic and decreasing domain stability. Thus, the combination of proteolytic cleavage and the destabilizing mutation trigger conformational changes that turn the LC pathogenic.
© 2020, Kazman et al.

Entities:  

Keywords:  AL amyloidosis; E. coli; antibody light chain; biochemistry; chemical biology; hydrophobic interactions; protein dynamics; protein stability

Mesh:

Substances:

Year:  2020        PMID: 32151314      PMCID: PMC7064341          DOI: 10.7554/eLife.52300

Source DB:  PubMed          Journal:  Elife        ISSN: 2050-084X            Impact factor:   8.140


  77 in total

1.  Sequences of mouse immunoglobulin light chain genes before and after somatic changes.

Authors:  O Bernard; N Hozumi; S Tonegawa
Journal:  Cell       Date:  1978-12       Impact factor: 41.582

2.  A Stable Mutant Predisposes Antibody Domains to Amyloid Formation through Specific Non-Native Interactions.

Authors:  Cardine N Nokwe; Manuel Hora; Martin Zacharias; Hisashi Yagi; Jirka Peschek; Bernd Reif; Yuji Goto; Johannes Buchner
Journal:  J Mol Biol       Date:  2016-01-29       Impact factor: 5.469

3.  The folding pathway of the antibody V(L) domain.

Authors:  Emma Rhiannon Simpson; Eva Maria Herold; Johannes Buchner
Journal:  J Mol Biol       Date:  2009-08-06       Impact factor: 5.469

4.  Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.

Authors:  Shaji Kumar; Angela Dispenzieri; Martha Q Lacy; Suzanne R Hayman; Francis K Buadi; Colin Colby; Kristina Laumann; Steve R Zeldenrust; Nelson Leung; David Dingli; Philip R Greipp; John A Lust; Stephen J Russell; Robert A Kyle; S Vincent Rajkumar; Morie A Gertz
Journal:  J Clin Oncol       Date:  2012-02-13       Impact factor: 44.544

5.  Hepatic amyloidosis: clinical appraisal in 77 patients.

Authors:  M A Gertz; R A Kyle
Journal:  Hepatology       Date:  1997-01       Impact factor: 17.425

Review 6.  Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment.

Authors:  Morie A Gertz
Journal:  Am J Hematol       Date:  2016-09       Impact factor: 10.047

7.  Thermodynamic and fibril formation studies of full length immunoglobulin light chain AL-09 and its germline protein using scan rate dependent thermal unfolding.

Authors:  Luis M Blancas-Mejía; Timothy J Horn; Marta Marin-Argany; Matthew Auton; Alexander Tischer; Marina Ramirez-Alvarado
Journal:  Biophys Chem       Date:  2015-08-04       Impact factor: 2.352

8.  Overview of the CCP4 suite and current developments.

Authors:  Martyn D Winn; Charles C Ballard; Kevin D Cowtan; Eleanor J Dodson; Paul Emsley; Phil R Evans; Ronan M Keegan; Eugene B Krissinel; Andrew G W Leslie; Airlie McCoy; Stuart J McNicholas; Garib N Murshudov; Navraj S Pannu; Elizabeth A Potterton; Harold R Powell; Randy J Read; Alexei Vagin; Keith S Wilson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2011-03-18

9.  Somatic hypermutation introduces insertions and deletions into immunoglobulin V genes.

Authors:  P C Wilson; O de Bouteiller; Y J Liu; K Potter; J Banchereau; J D Capra; V Pascual
Journal:  J Exp Med       Date:  1998-01-05       Impact factor: 14.307

10.  Immunoglobulin Light Chains Form an Extensive and Highly Ordered Fibril Involving the N- and C-Termini.

Authors:  Dennis W Piehl; Luis M Blancas-Mejía; Jonathan S Wall; Stephen J Kennel; Marina Ramirez-Alvarado; Chad M Rienstra
Journal:  ACS Omega       Date:  2017-02-27
View more
  12 in total

1.  Pharmacologic targeting of plasma cell endoplasmic reticulum proteostasis to reduce amyloidogenic light chain secretion.

Authors:  Bibiana Rius; Jaleh S Mesgarzadeh; Isabelle C Romine; Ryan J Paxman; Jeffery W Kelly; R Luke Wiseman
Journal:  Blood Adv       Date:  2021-02-23

2.  A Conservative Point Mutation in a Dynamic Antigen-binding Loop of Human Immunoglobulin λ6 Light Chain Promotes Pathologic Amyloid Formation.

Authors:  Daniele Peterle; Elena S Klimtchuk; Thomas E Wales; Florian Georgescauld; Lawreen H Connors; John R Engen; Olga Gursky
Journal:  J Mol Biol       Date:  2021-10-19       Impact factor: 5.469

Review 3.  Molecular Mechanism of Pathogenesis and Treatment Strategies for AL Amyloidosis.

Authors:  Hidehiko Ikura; Jin Endo; Hiroki Kitakata; Hidenori Moriyama; Motoaki Sano; Keiichi Fukuda
Journal:  Int J Mol Sci       Date:  2022-06-06       Impact factor: 6.208

Review 4.  Dynamic protein structures in normal function and pathologic misfolding in systemic amyloidosis.

Authors:  Emily Lewkowicz; Olga Gursky
Journal:  Biophys Chem       Date:  2021-10-14       Impact factor: 3.628

5.  Discovery of Potent Coumarin-Based Kinetic Stabilizers of Amyloidogenic Immunoglobulin Light Chains Using Structure-Based Design.

Authors:  Nicholas L Yan; Diogo Santos-Martins; Reji Nair; Alan Chu; Ian A Wilson; Kristen A Johnson; Stefano Forli; Gareth J Morgan; H Michael Petrassi; Jeffery W Kelly
Journal:  J Med Chem       Date:  2021-05-03       Impact factor: 7.446

6.  Breakdown of supersaturation barrier links protein folding to amyloid formation.

Authors:  Masahiro Noji; Tatsushi Samejima; Keiichi Yamaguchi; Masatomo So; Keisuke Yuzu; Eri Chatani; Yoko Akazawa-Ogawa; Yoshihisa Hagihara; Yasushi Kawata; Kensuke Ikenaka; Hideki Mochizuki; József Kardos; Daniel E Otzen; Vittorio Bellotti; Johannes Buchner; Yuji Goto
Journal:  Commun Biol       Date:  2021-01-26

7.  Cryo-EM reveals structural breaks in a patient-derived amyloid fibril from systemic AL amyloidosis.

Authors:  Lynn Radamaker; Julian Baur; Stefanie Huhn; Christian Haupt; Ute Hegenbart; Stefan Schönland; Akanksha Bansal; Matthias Schmidt; Marcus Fändrich
Journal:  Nat Commun       Date:  2021-02-08       Impact factor: 14.919

Review 8.  Molecular Mechanisms of Cardiac Amyloidosis.

Authors:  Yukihiro Saito; Kazufumi Nakamura; Hiroshi Ito
Journal:  Int J Mol Sci       Date:  2021-12-21       Impact factor: 5.923

9.  Analysis of the complete lambda light chain germline usage in patients with AL amyloidosis and dominant heart or kidney involvement.

Authors:  Natalie Berghaus; Sarah Schreiner; Martin Granzow; Carsten Müller-Tidow; Ute Hegenbart; Stefan O Schönland; Stefanie Huhn
Journal:  PLoS One       Date:  2022-02-25       Impact factor: 3.240

10.  Cu(II) Binding Increases the Soluble Toxicity of Amyloidogenic Light Chains.

Authors:  Rosaria Russo; Margherita Romeo; Tim Schulte; Martina Maritan; Luca Oberti; Maria Monica Barzago; Alberto Barbiroli; Carlo Pappone; Luigi Anastasia; Giovanni Palladini; Luisa Diomede; Stefano Ricagno
Journal:  Int J Mol Sci       Date:  2022-01-16       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.